tenofovir has been researched along with maraviroc in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.78) | 29.6817 |
| 2010's | 30 (83.33) | 24.3611 |
| 2020's | 5 (13.89) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abel, S; Muirhead, GJ; Ridgway, CE; Russell, D; Whitlock, LA | 1 |
| Curto, J; Niubo, J; Podzamczer, D; Tiraboschi, JM | 1 |
| Kaptur, PE; Mertenskoetter, T | 1 |
| Férir, G; Palmer, KE; Schols, D | 1 |
| Back, DJ; Else, LJ; Khoo, SH; Taylor, S | 1 |
| Fang, J; Jadhav, PR | 1 |
| Acosta, EP; Barreca, ML; Chirullo, B; Collins, M; Della Corte, A; Greenhouse, J; Iraci, N; Lewis, MG; Norelli, S; Savarino, A; Shytaj, IL; Yalley-Ogunro, J | 1 |
| Craig, C; Fätkenheuer, G; Heera, J; Leal, M; McFadyen, L; Mildvan, D; Mills, A; Podzamczer, D; Portsmouth, S; Rinehart, AR; Than, S; Valdez, H; Valluri, SR; Vourvahis, M | 1 |
| Bennett, LJ; Grooms-Williams, TW; Hamorsky, KT; Husk, AS; Matoba, N; Palmer, KE | 1 |
| Feucht, N; Hadeler, J; Lanzl, I; Loos, D; Schmid, RM; Schwerdtfeger, C; Spinner, CD | 1 |
| Binet, L; Djerada, Z; Feliu, C; Gozalo, C; Lamiable, D; Marty, H; Millart, H; Robinet, A; Tournois, C; Vautier, D | 1 |
| McGowan, I | 1 |
| Achhra, AC; Boyd, MA; Cooper, DA; Kelleher, AD; Law, MG; Matthews, GV | 1 |
| Akkina, R; Kashuba, ADM; LeCureux, J; Remling-Mulder, L; Sykes, C; Veselinovic, M; Yang, KH | 1 |
| Cohen, MS; Emerson, CW; Fedoriw, Y; Geller, EJ; Kashuba, AD; Nelson, JA; Nicol, MR; Patterson, KB; Prince, HM; Sykes, C | 1 |
| De La Mata, FJ; Gómez, R; Jiménez, JL; Muñoz-Fernández, MÁ; Sánchez-Rodríguez, J; Sepúlveda-Crespo, D; Serramía, MJ | 1 |
| Berzins, B; Brown, T; Chan, ES; Eron, JJ; Fichtenbaum, CJ; Klingman, KL; Landay, A; Ofotokun, I; Ribaudo, H; Robertson, K; Taiwo, BO; Tsibris, A | 1 |
| Anderson, PL; Bushman, LR; Chuong, D; Dobard, CW; Garcia-Lerma, JG; Hanson, D; Heneine, W; McGowan, I; Pau, CP; Rohan, L; Sharma, S; Taylor, A; Wang, L | 1 |
| Chen, J; Li, L; Qin, C; Ren, Y; Wan, Y; Wang, J; Wang, W; Wei, Q; Xu, J; Zhang, X | 1 |
| Golan-Paz, S; Jiang, Y; Ramanathan, R; Read, B; Woodrow, KA | 1 |
| Allmon, A; Cottrell, ML; Dellon, ES; Hudgens, MG; Kashuba, AD; Madanick, RD; Malone, S; Mollan, KR; Patterson, KB; Prince, HM; Shaheen, NJ; Sykes, C; White, N | 1 |
| Baum, MM; Butkyavichene, I; Churchman, SA; Easley, JT; Fanter, R; Gunawardana, M; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Smith, TJ; Yang, F | 1 |
| Brown, TT; Chan, ES; Eron, JJ; Fichtenbaum, CJ; Klingman, KL; Landay, AL; Martinson, J; Mirmonsef, P; Ofotokun, I; Plants, J; Ribaudo, HJ; Taiwo, BO; Weitzmann, MN | 1 |
| Berzins, B; Brown, TT; Chan, ES; Eron, JJ; Lee, A; Miyahara, S; Robertson, KR; Rusin, D; Taiwo, BO | 1 |
| Brochier, C; Cottalorda-Dufayard, J; Cotte, L; Dellamonica, P; Durant, J; Gagnieu, MC; Gatey, C; Izopet, J; Jacomet, C; Lucht, F; Pradat, P; Raffi, F; Trabaud, MA; Vassallo, M | 1 |
| Blakney, AK; Jiang, Y; Little, AB; Woodrow, KA | 1 |
| Anton, PA; Baum, MM; Butkyavichene, I; Churchman, SA; Cortez, JM; Dawson, L; Fanter, R; Gunawardana, M; Guthrie, KM; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Olive, TJ; Pyles, RB; Rosen, RK; Vargas, SE; Vincent, KL; Yang, F | 1 |
| Amico, KR; Andrade, A; Chege, W; Chen, YQ; Gulick, RM; Kapadia, SN; Landovitz, RJ; Mayer, KH; McCauley, M; Schackman, BR; Wilkin, TJ; Wu, C | 1 |
| Brown, TT; Landay, A; Masters, MC; Miyahara, S; Robertson, K; Taiwo, BO; Vecchio, A | 1 |
| Adamson, L; Akkina, R; Blake, K; Burgunder, EM; Devanathan, AS; Garcia, JV; Kashuba, ADM; Kovarova, M; Luciw, P; Pirone, JR; Remling-Mulder, L; Rosen, EP; Schauer, AP; Srinivas, N; Sykes, C; White, NR | 1 |
| Cottrell, M; Dellon, ES; Gonzalez, D; Kashuba, ADM; Madanick, RD; Maffuid, K; Nelson, JAE; Prince, HA; Shaheen, NJ; Srinivas, N; Sykes, C; White, N | 1 |
| Avenant, C; Dlamini, S; Enfield, K; Hapgood, JP; Kuipa, M | 1 |
| Brown, TT; Chege, W; Chen, YQ; Gulick, RM; Hendrix, CW; Klingman, KL; Landovitz, RJ; Marzinke, MA; Mayer, KH; Mccauley, MB; Wilkin, TJ; Yuhas, K | 1 |
| Amico, KR; Andrew, P; Chege, W; Chen, YQ; Cottle, LM; Eshleman, SH; Farley, JE; Frank, I; Gulick, RM; Hendrix, CW; Ho, K; Landovitz, RJ; Liu, AY; Magnus, M; Marcus, C; Marzinke, MA; Mayer, KH; McCauley, M; Richardson, P; Rinehart, AR; Rooney, JF; Salata, RA; Santana, J; Stekler, JD; Wilkin, T; Yuhas, K | 1 |
4 review(s) available for tenofovir and maraviroc
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Update on microbicide research and development - seeking new HIV prevention tools for women.
Topics: Adenine; Administration, Intravaginal; Adult; Africa South of the Sahara; Anti-HIV Agents; Anti-Infective Agents; Clinical Trials as Topic; Cyclohexanes; Drug Discovery; Female; HIV Infections; Humans; Male; Maraviroc; Organophosphonates; Pyridines; Pyrimidines; Tenofovir; Triazoles; Urea | 2011 |
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Topics: Adenine; Adult; Amniotic Fluid; Anti-HIV Agents; Cyclohexanes; Enfuvirtide; Female; Fetal Blood; Fetus; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Maraviroc; Nevirapine; Organophosphonates; Peptide Fragments; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles; Viral Load; Zidovudine | 2011 |
An overview of antiretroviral pre-exposure prophylaxis of HIV infection.
Topics: Adenine; Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; Female; HIV Infections; Humans; Male; Maraviroc; Medication Adherence; Nitriles; Organophosphonates; Pre-Exposure Prophylaxis; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Triazoles | 2014 |
11 trial(s) available for tenofovir and maraviroc
| Article | Year |
|---|---|
The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Organophosphonates; Receptors, CCR5; Statistics as Topic; Tenofovir; Triazoles; Trimethoprim, Sulfamethoxazole Drug Combination | 2008 |
From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.
Topics: Adenine; Anti-HIV Agents; Cyclohexanes; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Male; Maraviroc; Models, Biological; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; RNA, Viral; Tenofovir; Triazoles | 2012 |
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Triazoles; Viral Load; Young Adult | 2013 |
Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.
Topics: Adult; Anti-HIV Agents; Bone Density; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Pelvic Bones; Tenofovir; Triazoles | 2015 |
Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Cyclohexanes; Darunavir; Double-Blind Method; Emtricitabine; Female; Flow Cytometry; HIV Infections; Humans; Male; Maraviroc; Placebos; Prospective Studies; Tenofovir; Treatment Outcome; Triazoles | 2016 |
Neurocognition with maraviroc compared with tenofovir in HIV.
Topics: Adult; AIDS-Related Complex; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cognition; Cyclohexanes; Double-Blind Method; Female; HIV Infections; Humans; Male; Maraviroc; Neuropsychological Tests; Placebos; Tenofovir; Treatment Outcome; Triazoles; United States | 2016 |
Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Maintenance Chemotherapy; Male; Maraviroc; Middle Aged; Raltegravir Potassium; Tenofovir; Treatment Outcome; Triazoles; Viral Load; Young Adult | 2016 |
Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Topics: Administration, Intravaginal; Adult; Anti-HIV Agents; Contraceptive Devices, Female; Cross-Over Studies; Drug Compounding; Drug Delivery Systems; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Maraviroc; Patient Satisfaction; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2018 |
No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305.
Topics: Adolescent; Adult; Aged; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Quality of Life; Tenofovir; United States | 2018 |
Limited correlation between systemic biomarkers and neurocognitive performance before and during HIV treatment.
Topics: Adult; AIDS Dementia Complex; Anti-HIV Agents; Biomarkers; Darunavir; Double-Blind Method; Emtricitabine; Female; HIV Infections; Humans; Inflammation; Male; Maraviroc; Ritonavir; Tenofovir | 2020 |
Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Emtricitabine; Female; HIV Infections; Humans; Male; Maraviroc; Tenofovir | 2022 |
21 other study(ies) available for tenofovir and maraviroc
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Chromatography, Liquid; Cyclohexanes; Didanosine; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Tandem Mass Spectrometry; Tenofovir; Triazoles; Viral Load | 2010 |
Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.
Topics: Adenine; Algal Proteins; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Cyclohexanes; Drug Synergism; Enfuvirtide; Genotype; HIV Envelope Protein gp41; HIV-1; Humans; Lectins; Leukocytes, Mononuclear; Maraviroc; Microbial Sensitivity Tests; Organophosphonates; Peptide Fragments; Plant Lectins; Tenofovir; Triazoles | 2011 |
A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.
Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Flow Cytometry; Fluorescent Antibody Technique; Macaca mulatta; Maraviroc; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Simian Acquired Immunodeficiency Syndrome; Sulfonamides; T-Lymphocyte Subsets; Tenofovir; Triazoles; Viral Load; Viremia | 2012 |
Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides.
Topics: Adenine; Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Antiviral Agents; Chromatography, Affinity; Cyclohexanes; Drug Combinations; Drug Synergism; Genetic Vectors; HIV Antibodies; HIV Envelope Protein gp120; HIV-1; Humans; Immunoglobulin G; Maraviroc; Neutralization Tests; Nicotiana; Organophosphonates; Plant Lectins; Recombinant Proteins; Tenofovir; Tobamovirus; Triazoles | 2013 |
[Ophthalmological alterations at the initial diagnosis of HIV infection].
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Early Diagnosis; Emtricitabine; Eye Infections, Viral; HIV Infections; Humans; Lopinavir; Male; Maraviroc; Organophosphonates; Retinal Diseases; Syndrome; Tenofovir; Treatment Outcome; Triazoles; Zidovudine | 2014 |
Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology.
Topics: Adenine; Anti-Retroviral Agents; Chromatography, High Pressure Liquid; Cyclohexanes; Humans; Maraviroc; Mass Spectrometry; Nitriles; Organophosphonates; Proline; Pyridazines; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Tandem Mass Spectrometry; Tenofovir; Time Factors; Triazoles | 2013 |
Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclohexanes; Cyclopropanes; Dideoxynucleosides; Feasibility Studies; Female; Humans; Male; Maraviroc; Middle Aged; Organophosphonates; Ritonavir; Tenofovir; Triazoles | 2014 |
HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
Topics: Adenine; Animals; Anti-HIV Agents; Cyclohexanes; Disease Models, Animal; Female; HIV Infections; HIV-1; Humans; Maraviroc; Mice; Mucous Membrane; Organophosphonates; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles; Virus Internalization | 2014 |
Models for predicting effective HIV chemoprevention in women.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cell Culture Techniques; Cell Survival; Chemoprevention; Chromatography, Liquid; Cyclohexanes; Disease Transmission, Infectious; Dose-Response Relationship, Drug; Female; HIV Infections; Humans; Maraviroc; Middle Aged; Organ Culture Techniques; Organophosphonates; Tandem Mass Spectrometry; Tenofovir; Triazoles; Vagina; Viral Load; Young Adult | 2015 |
Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission.
Topics: Adenine; Animals; Anti-HIV Agents; Anti-Infective Agents; Antiviral Agents; Cell Survival; Cyclohexanes; Dendrimers; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Maraviroc; Mice; Mice, Inbred BALB C; Mucous Membrane; Organophosphonates; Silanes; Software; Tenofovir; Triazoles; Vagina | 2015 |
Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.
Topics: Administration, Topical; Animals; Anti-HIV Agents; Cross-Over Studies; Cyclohexanes; Disease Models, Animal; Disease Transmission, Infectious; Gels; Macaca; Maraviroc; Placebos; Simian Acquired Immunodeficiency Syndrome; Tenofovir; Treatment Outcome; Triazoles | 2015 |
Mucosal Topical Microbicide Candidates Exert Influence on the Subsequent SIV Infection and Survival by Regulating SIV-Specific T-Cell Immune Responses.
Topics: Administration, Rectal; Animals; Anti-Infective Agents, Local; CD4-Positive T-Lymphocytes; Cyclohexanes; Disease Progression; Gene Expression Profiling; Humans; Immunity, Cellular; Macaca mulatta; Maraviroc; Mucous Membrane; Oligonucleotide Array Sequence Analysis; Peptides; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Survival Rate; Tenofovir; Triazoles; Viral Load | 2016 |
Biophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application.
Topics: Administration, Topical; Animals; Anti-HIV Agents; Biophysical Phenomena; Body Fluids; Cell Line; Cell Survival; Chemoprevention; Cryoelectron Microscopy; Cyclohexanes; Detergents; Drug Liberation; Female; HIV-1; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Lipid Bilayers; Liposomes; Maraviroc; Mice, Inbred C57BL; Mucous Membrane; Nanoparticles; Small Molecule Libraries; Tenofovir; Triazoles | 2016 |
Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design.
Topics: Adult; Anti-HIV Agents; Biomarkers; Body Fluids; Cervix Uteri; Clinical Trials as Topic; Cyclohexanes; Emtricitabine; Female; Healthy Volunteers; Humans; Maraviroc; Raltegravir Potassium; Rectum; Tenofovir; Triazoles; Vagina | 2016 |
Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model.
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Contraceptive Devices, Female; Cyclohexanes; Delayed-Action Preparations; Drug Combinations; Female; HIV Infections; Humans; Maraviroc; Models, Animal; Primary Prevention; Sheep; Tenofovir; Triazoles; Vagina | 2016 |
In vitro-ex vivo correlations between a cell-laden hydrogel and mucosal tissue for screening composite delivery systems.
Topics: Animals; Chemistry, Pharmaceutical; Cyclohexanes; Delayed-Action Preparations; Drug Delivery Systems; Female; Hydrogel, Polyethylene Glycol Dimethacrylate; Lactic Acid; Macaca nemestrina; Maraviroc; Methacrylates; Mucous Membrane; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Primates; Pyrimidines; Tenofovir; Triazoles; Vagina | 2016 |
Antiretroviral Penetration across Three Preclinical Animal Models and Humans in Eight Putative HIV Viral Reservoirs.
Topics: Animals; Anti-HIV Agents; Anti-Retroviral Agents; Atazanavir Sulfate; Emtricitabine; Female; HIV Infections; Humans; In Vitro Techniques; Maraviroc; Mice; Raltegravir Potassium; Tenofovir | 2019 |
Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cohort Studies; Computer Simulation; Demography; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Maraviroc; Pre-Exposure Prophylaxis; Reproductive Tract Infections; Tenofovir; Treatment Outcome | 2020 |
Maraviroc, tenofovir disoproxil fumarate and dapivirine, activate progesterone receptor B in the absence of progestogens.
Topics: Anti-HIV Agents; Binding, Competitive; Cell Line; Contraceptive Agents, Hormonal; HIV Infections; HIV-1; Humans; Immunologic Factors; In Vitro Techniques; Levonorgestrel; Maraviroc; Phosphorylation; Progesterone Congeners; Pyrimidines; Receptors, Progesterone; Tenofovir; Transcriptional Activation | 2020 |
Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305).
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Maraviroc; Medication Adherence; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Sexual Behavior; Tenofovir | 2022 |